It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Typical and atypical dopamine uptake inhibitors (DUIs) prefer distinct conformations of the dopamine transporter (DAT) to form ligand-transporter complexes, resulting in markedly different effects on behavior, neurochemistry, and potential for addiction. Here we show that cocaine and cocaine-like typical psychostimulants elicit changes in DA dynamics distinct from those elicited by atypical DUIs, as measured via voltammetry procedures. While both classes of DUIs reduced DA clearance rate, an effect significantly related to their DAT affinity, only typical DUIs elicited a significant stimulation of evoked DA release, an effect unrelated to their DAT affinity, which suggests a mechanism of action other than or in addition to DAT blockade. When given in combination, typical DUIs enhance the stimulatory effects of cocaine on evoked DA release while atypical DUIs blunt them. Pretreatments with an inhibitor of CaMKIIα, a kinase that interacts with DAT and that regulates synapsin phosphorylation and mobilization of reserve pools of DA vesicles, blunted the effects of cocaine on evoked DA release. Our results suggest a role for CaMKIIα in modulating the effects of cocaine on evoked DA release without affecting cocaine inhibition of DA reuptake. This effect is related to a specific DAT conformation stabilized by cocaine. Moreover, atypical DUIs, which prefer a distinct DAT conformation, blunt cocaine’s neurochemical and behavioral effects, indicating a unique mechanism underlying their potential as medications for treating psychostimulant use disorder.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Intramural Research Program, Medication Development Program, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913); New York Institute of Technology, Department of Biological and Chemical Science, Old Westbury, USA (GRID:grid.260914.8) (ISNI:0000 0001 2322 1832)
2 Intramural Research Program, Biobehavioral Imaging & Molecular Neuropsychopharmacology Unit, Neuroimaging Research Branch, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913); Universitat de Barcelona, Department of Pathology and Experimental Therapeutics, Institut de Neurociències, L’Hospitalet de Llobregat, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
3 Medical University of Vienna, Center for Physiology and Pharmacology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
4 Intramural Research Program, Medication Development Program, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913)
5 Intramural Research Program, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913)
6 Intramural Research Program, Biobehavioral Imaging & Molecular Neuropsychopharmacology Unit, Neuroimaging Research Branch, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913)
7 Intramural Research Program, Medication Development Program, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913); Intramural Research Program, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Baltimore, USA (GRID:grid.419475.a) (ISNI:0000 0000 9372 4913)